Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

Chi­nook Ther­a­peu­tics said it tem­porar­i­ly halt­ed dos­ing par­tic­i­pants in the Phase I tri­al of its treat­ment for an ul­tra-rare ge­net­ic kid­ney dis­ease af­ter one of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER